CD9 participates in endothelial cell migration during in vitro wound repair

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 2, 2000, Pages 360-369

  Klein Soyer, Claudine ^a   Azorsa, David O ^b   Cazenave, Jean Pierre ^a   Lanza, François ^a  

^a INSERM   (France)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

CD9; Cell migration; Endothelial cells; Integrins; Wound repair

Indexed keywords

BETA1 INTEGRIN; BETA3 INTEGRIN; CD63 ANTIGEN; CD9 ANTIGEN; FIBRONECTIN; IMMUNOGLOBULIN G; INTEGRIN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VITRONECTIN;

ANGIOGENESIS; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MAMMARY ARTERY; PRIORITY JOURNAL; SAPHENOUS VEIN; WOUND HEALING;

EID: 0033952054     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.2.360     Document Type: Article

References (62)

1. Maecker HT, Todd SC, Levy S. The tetraspanin superfamily: molecular facilitators. FASEB J. 1997;11:428-442.
2. Wright MD, Tomlinson MG. The ins and outs of the transmembrane 4 superfamily. Immunol Today. 1994;15:588-594.
3. Si Z, Hersey P. Expression of the neuroglandular antigen and analogues in melanoma: CD9 expression appears inversely related to metastatic potential of melanoma. Int J Cancer. 1993;54:37-43.
4. Miyake M, Nakano K, Itoi S-I, Koh T, Taki T. Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer. Cancer Res. 1996;56:1244-1249.
5. Anton ES, Hadjiargyrou M, Patterson PH, Matthew WD. CD9 plays a role in Schwann cell migration in vitro. J Neurosci. 1995;15:584-595.
6. Zola H, Furness V, Barclay S, Zowtyj H, Smith M, Melo JV, Neoh SH, Bradley J. The p24 leucocyte membrane antigen: modulation associated with lymphocyte activation and differentiation. Immunol Cell Biol. 1989; 67:63-70.
7. Scherberich A, Moog S, Haan-Archipoff G, Azorsa DO, Lanza F, Beretz A. Tetraspanin CD9 is associated with very late-acting integrins in human vascular smooth muscle cells and modulates collagen matrix reorganization. Arterioscler Thromb Vasc Biol. 1998;18:1691-1697.
8. Lanza F, Wolf D, Fox CF, Kieffer N, Seyer JM, Fried VA, Coughlin SR, Phillips DR, Jennings LK. cDNA cloning and expression of platelet p24/CD9: evidence for a new family of multiple membrane-spanning proteins. J Biol Chem. 1991;266:10638-10645.
9. 1 integrin-dependent motility on fibronectin and laminin substrates and enhanced tyrosine phosphorylation. J Biol Chem. 1995;270:24092-24099.
10. Ikeyama S, Koyama M, Yamaoko M, Sasada R, Miyake M. Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA. J Exp Med. 1993;177:1231-1237.
11. Rubinstein E, Le Naour F, Billard M, Prenant M, Boucheix C. CD9 antigen is an accessory subunit of the VLA integrin complexes. Eur J Immunol. 1994;24:3005-3013.
12. Forsyth KD. Anti-CD9 antibodies augment neutrophil adherence to endothelium. Immunology. 1991;72:292-296.
13. Masselis-Smith A, Shaw RE. CD9-Regulated adhesion: anti-CD9 monoclonal antibody induce pre-B cell adhesion to bone marrow fibroblasts through de novo recognition of fibronectin. J Immunol. 1994;152: 2768-2777.
14. Hadjiargyrou M, Patterson PH. An anti-CD9 monoclonal antibody promotes adhesion and induces proliferation of Schwann cells in vitro. J Neurosci. 1995;15:574-583.
15. syk in human platelets. J Biol Chem. 1995;270: 15119-15124.
16. 2+ store depletion. J Immunol. 1995;155: 4427-4436.
17. Slupsky JR, Seehafer JG, Tang SC, Masellis-Smith A, Shaw AR. Evidence that monoclonal antibodies against CD9 antigen induce specific association between CD9 and the platelet glycoprotein IIb-IIIa complex. J Biol Chem. 1989;264:12289-12293.
18. 3 integrin) on activated platelet pseudopods and α-granule membranes. Histochem J. 1997;29: 153-165.
19. Indig FE, Diaz-Gonzalez F, Ginsberg MH. Analysis of the tetraspanin CD9-integrin αIIbβ3 (GPIIb-IIIa) complex in platelet membranes and transfected cells. Biochem J. 1997;327:291-298.
20. Nieuwenhuis HK, van Oosterhout JJG, Rozemuller E, van Iwaarden F, Sixma JJ. Studies with a monoclonal antibody against activated platelets: evidence that a secreted 53,000-molecular weight lysosome-like granule protein is exposed on the surface of activated platelets in the circulation. Blood. 1987;70:838-845.
21. Vischer UM, Wagner DD. CD63 is a component of Weibel-Palade bodies of human endothelial cells. Blood. 1993;82:1184-1191.
22. Berditchevski F, Bazzoni G, Hemler ME. Specific association of CD63 with the VLA-3 and VLA-6 integrins. J Biol Chem. 1995;270: 17784-17790.
23. Klein-Soyer C, Beretz A, Cazenave J-P, Driot F, Maffrand J-P. Behavior of confluent endothelial cells after irradiation. Modulation of wound repair by heparin and fibroblast growth factor. Biol Cell. 1990;68: 231-238.
24. Klein-Soyer C, Archipoff G, Beretz A, Cazenave J-P. Opposing effects of heparin with TGF-β or aFGF during repair of a mechanical wound of human endothelium. Influence of cAMP on cell migration. Biol Cell. 1992;75:155-162.
25. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
26. Brooks PC. Role of integrins in angiogenesis. Eur J Cancer. 1996;32A: 2423-2429.
27. Hemler ME, Mannion BA, Berditchevski F. Association of TM4SF proteins with integrins: relevance to cancer. Biochim Biophys Acta. 1996; 1287:67-71.
28. Ruoslahti E, Haymann EG, Pierschbacher M, Engvall E. Fibronectin: purification, immunochemical properties and biological activities. Methods Enzymol. 1982;82:803-831.
29. Preissner KT, Wassmuth R, Müller-Bergbaus G. Physicochemical characterization of human S-protein and its function in the blood coagulation system. Biochem J. 1985;231:349-355.
30. Azorsa DO, Cazenave J-P, Lanza F. Analysis of antibodies recognizing CD9 and use of glutathione S-transferase fusion proteins to screen for monoclonal antibodies to CD9 and other members of the transmembrane 4 superfamily. In: Kishimoto T, ed. Leucocyte Typing VI. New York, NY: Garland Publishing Inc; 1997:631-632.
31. Ravanat C, Morales M, Azorsa DO, Moog S, Schuhler S, Grunert P, Loew D, van Dorsselaer A, Cazenave J-P, Lanza F. Gene cloning of rat and mouse platelet glycoprotein V: identification of megakaryocyte-specific promoters and demonstration of functional thrombin cleavage. Blood. 1997;89:3253-3262.
32. Hildreth JEK, Derr D, Azorsa DO. Characterization of a novel self-associating Mr 40,000 platelet glycoprotein. Blood. 1991;77:121-132.
33. Azorsa DO, Hyman JA, Hildreth JEK. CD63/Pltgp40: a platelet activation antigen identical to the stage specific melanoma-associated antigen ME491 Blood. 1991;78:280-284.
34. Rosenfeld SI, Looney RJ, Leddy JP, Phipps DC, Abraham GN, Anderson CL. Human platelet Fc receptor for immunoglobulin G: identification as a 40,000-molecular weight membrane protein shared by monocytes. J Clin Invest. 1985;76:2317-2322.
35. Klein-Soyer C, Cazenave J-P. Culture de cellules endothéliales vasculaires humaines. In: Sultan Y, Fischer AM, eds. Physiopathologie de l'Hémostase et de la Thrombose: Progrès en Hématologie. Paris, France: Doin Editeurs; 1986;8:83-93.
36. Mazzucotelli J-P, Klein-Soyer C, Beretz A, Brisson C, Archipoff G, Cazenave J-P. Endothelial cell seeding: coating of Dacron and expanded polytetrafluoroethylene vascular grafts with a biological glue allows adhesion and growth of human saphenous vein endothelial cells. Int J Artif Organs. 1991;14:482-490.
37. Gillies RJ, Didier N, Denton M. Determination of cell number in monolayer cultures. Anal Biochem. 1986;159:109-113.
38. Klein-Soyer C, Beretz A, Cazenave J-P, Wittendorp-Rechenmann E, Vonesch J-L, Rechenmann RV, Driot F, Maffrand J-P. Sulfated polysaccharides modulate effects of acidic and basic fibroblast growth factors on repair of injured confluent human vascular endothelium. Arteriosclerosis. 1989;9:147-153.
39. Klein-Soyer C, Cazenave J-P, Herbert J-M, Maffrand J-P. SR 25989 inhibits healing of a mechanical wound of confluent human saphenous vein endothelial cells which is modulated by standard heparin and growth factors. J Cell Physiol. 1994;160:316-322.
40. Labourdette G, Janet T, Laeng P, Perraud F, Lawrence D, Pettmann B. Transforming growth factor-β modulates the effects of basic fibroblast growth factor on growth and phenotypic expression of rat astroblast in vitro. J Cell Physiol. 1990;144:473-484.
41. 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen. J Cell Biol. 1992;117:1101-1107.
42. 3-mediated endothelial cell migration is triggered through distinct signaling mechanisms. J Cell Biol. 1993;121:163-170.
43. 1 integrin-mediated adhesion of leukemic cells to the central cell-binding domain of fibronectin. Cell Growth Differ. 1997;8: 1339-1347.
44. Defilippi P, Bozzo C, Volpe G, Romano G, Venturino M, Silengo L, Tarone G. Integrin-mediated signal transduction in human endothelial cells: analysis of tyrosine phosphorylation events. Cell Adhes Commun. 1994;2:75-86.
45. 1 integrin precursor. Eur J Immunol. 1997;27:1919-1927.
46. Moses MA, Langer R. Inhibitors of angiogenesis. Biotechnology. 1991; 9:630-634.
47. Risau W. Differentiation of endothelium. FASEB J. 1995;9:926-933.
48. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-364.
49. Folkman J. What is the evidence that tumors are angiogenesis dependent ? J Natl Cancer Inst. 1990;82:4-6.
50. 3 for angiogenesis. Science. 1994;264:569-571.
51. Bischoff J. Approaches to studying cell adhesion molecules in angiogenesis. Trends Cell Biol. 1995;5:60-65.
52. Strömblad S, Cheresh DA. Cell adhesion and angiogenesis. Trends Cell Biol. 1996;6:462-468.
53. Sincock PM, Fitter S, Parton RG, Berndt MC, Gamble JR, Ashman LK. PETA-3/CD151, a member of the transmembrane 4 superfamily, is localised to the plasma membrane and endocytic system of endothelial cells, associates with multiple integrins and modulates cell function. J Cell Sci. 1999;833-844.
54. 1 integrin localized at endothelial lateral junctions. J Cell Biol. 1998;141:791-804.
55. Klein-Soyer C, Beretz A, Millon-Collard R, Abecassis J, Cazenave J-P. A simple in vitro model of mechanical injury of confluent cultured endothelial cells to study quantitatively the repair process. Thromb Haemost. 1986;56:232-235.
56. Worthington RE, Carroll RC, Boucheix C. Platelet activation by CD9 monoclonal antibodies is mediated by the FcγII receptor. Br J Haematol. 1990;74:216-222.
57. Griffith L, Slupsky J, Seehafer J, Boshkov L, Shaw ARE. Platelet activation by immobilized monoclonal antibody: evidence for a CD9 proximal signal. Blood. 1991;78:1753-1759.
58. Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. Cell. 1996;84:359-369.
59. Giancotti G. Integrin signaling: specificity and control of cell survival and cell cycle progression. Curr Opin Cell Biol. 1997;5:691-700.
60. Jennings LK, Wilkinson DA, Crossno JT Jr. CD9 is a cell adhesion molecule on human platelets. Blood. 1995;86:282a.
61. Crossno JT Jr, Poppleton HM, White MM, Wilkinson DA, Patterson KS, Raghow R, Jennings LK. The large extracellular loop of p24/CD9 contributes to cell motility and spreading on fibronectin. Blood. 1995; 86:282a. Abstract.
62. Slupsky JR, Cawley JC, Kaplan C, Zuzel M. Analysis of CD9, CD32 and p67 signalling: use of degranulated platelets indicates direct involvement of CD9 and p67 in integrin activation. Br J Haematol. 1997;96:275-286.